Overview

Efficacy of Candesartan on Symptomatic Heart Failure in Treating Diabetic and Hypertensive Patients.

Status:
Completed
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the effects of candesartan, once daily (QD), on the N-terminal pro-B-type Natriuretic Peptide laboratory marker in subjects with symptomatic heart failure with diastolic dysfunction.
Phase:
Phase 3
Details
Lead Sponsor:
Takeda
Treatments:
Adrenergic beta-Antagonists
Angiotensin-Converting Enzyme Inhibitors
Candesartan
Candesartan cilexetil
Enzyme Inhibitors